FAQs

The justification of the treatment interval is based on

 

• Pharmacokinetic/Pharmacodynamic (PK/PD) modelling to define an
  appropriate dosage regimen for antibiotics;
• in-vitro data (killing activity and Post antibiotic effect) in conjunction with
  PK data giving evidence that the antibiotic combination provides a strong
  and sustained antibacterial effect at concentrations that occur in vivo;
• Two clinical field trials demonstrating clinical efficacy of Ubrolexin compared
  with two different control products when Ubrolexin® was administered at 24h interval.

Aggressive intramammary antibiotic treatment (injector application at every milking) is sometimes advocated to increase cure of clinical mastitis cases. For Ubrolexin® with the synergistic action of its two ingredients and its proven post-antibiotic effect, more frequent administrations are not required: a fast kill of most pathogens is achieved within the first hours following Ubrolexin® administration and the post-antibiotic effect prevents the bacterial colonies from re-growing.

A resistance to either Cefalexin or Kanamycin does not necessarily result in resistance to Ubrolexin®. Resistance is usually expressed as an MIC value higher than the recommended breakpoint. However, synergistic activity between two components often results in a MIC breakpoint of the combination which is lower than the breakpoints of the individual components. Therefore, the use of Ubrolexin® may be a way to overcome existing resistance to one or the other compound.

The combination of Cefalexin and Kanamycin in Ubrolexin® is justified by broadening of the spectrum of activity, additive and/or synergistic effects, enhanced antibacterial kill activity, reduced MIC values for the individual antimicrobial when combined and a reduced risk of selecting for resistant strains.

Ubrolexin® is indicated for the treatment of clinical mastitis due to Staphylococcus aureus, Streptococcus dysgalactiae, Streptococcus uberis and Escherichia coli. In addition, in vitro studies have shown that isolates of S. agalactiae and coagulase-negative staphylococci are susceptible to the combination of Cefalexin and Kanamycin.